# Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

> clinical trial · VERIFIED · 2026-08-28

Status: RECRUITING · Sponsor: Syndax Pharmaceuticals · Condition: Acute Myeloid Leukemias

- Company: Syndax Pharmaceuticals
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07211958

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.